(Yicai Global) June 17 -- Wuhan Institute of Biological Products released the results of the first and second phases of its clinical tests of its inactivated vaccine for Covid-19 -- the world’s first to gain approval -- saying those vaccinated all generated high-titer antibodies and suffered no major adverse reactions.

The institute under China National Biotec Group, a unit of Beijing-based China National Pharmaceutical Group, used randomness, double blindness and placebo control for the first and second phases of clinical tests, it said in Beijing yesterday while releasing the results. The vaccine became the first green lighted for clinical tests on April 12, and the two test sequences started at the same time in Wuzhi county in eastern Henan province.

The antibody titer test detects the presence and gauges the amount of antibodies in the blood. Their amount and diversity correlates to the strength of the immune response.

The tests focused on the post-vaccination cellular immune changes in healthy subjects between the ages of 18 and 59, with 1,120 in the first and second groups all having two injections.

In a double blind test both the subject and observer are unaware the exercise is a test. Deemed the gold standard. Double blind tests are used in both theoretical and practical experiments in medicine and psychology.

Editor: Ben Armour